OCN Cancer Treatment Modalities 2 — Questions and Answers
Question 1: Which of the following is a cell-cycle-specific chemotherapy agent?
- Cyclophosphamide
- Carmustine
- Vincristine (Correct answer)
- Cisplatin
Correct answer: Vincristine
Vincristine is cell-cycle-specific, acting in the M phase by binding to tubulin and preventing spindle formation.
Question 2: What cumulative dose of doxorubicin is associated with the greatest risk of cardiomyopathy?
- 100 mg/m²
- 200 mg/m²
- 450–550 mg/m² (Correct answer)
- 750 mg/m²
Correct answer: 450–550 mg/m²
Cardiotoxicity from doxorubicin significantly increases when the cumulative dose exceeds 450–550 mg/m².
Question 3: A patient receiving irinotecan develops profuse diarrhea within 24 hours of infusion. This is best managed with:
- Loperamide
- Atropine (Correct answer)
- Octreotide
- Metoclopramide
Correct answer: Atropine
Early-onset diarrhea with irinotecan is cholinergic in nature and is treated with atropine.
Question 4: Which type of radiation therapy delivers a high dose to a small target with steep dose fall-off, minimizing exposure to surrounding tissue?
- Conventional fractionated radiotherapy
- Stereotactic radiosurgery (SRS) (Correct answer)
- Total body irradiation
- Brachytherapy
Correct answer: Stereotactic radiosurgery (SRS)
Stereotactic radiosurgery (SRS) delivers high-dose, precise radiation to a small target using multiple beams that converge, sparing surrounding tissue.
Question 5: Which of the following is a common dose-limiting toxicity of cisplatin?
- Pulmonary fibrosis
- Nephrotoxicity (Correct answer)
- Cardiotoxicity
- Hepatotoxicity
Correct answer: Nephrotoxicity
Cisplatin causes significant nephrotoxicity; aggressive hydration and amifostine may be used to minimize renal damage.
Question 6: Hormonal therapy with tamoxifen is most appropriate for which breast cancer receptor profile?
- HER2-positive, ER-negative
- Triple-negative
- Estrogen receptor-positive (Correct answer)
- PR-negative, ER-negative
Correct answer: Estrogen receptor-positive
Tamoxifen is a selective estrogen receptor modulator (SERM) used in estrogen receptor-positive breast cancers.
OCN Cancer Treatment Modalities 2
Which of the following is a cell-cycle-specific chemotherapy agent?